To date, genome-wide association studies in NAFLD/NASH research identified several genetic variations such as polymorphisms of PNPLA3, transmembrane 6 superfamily member 2 (TM6SF2), farnesyl diphosphate farnesyl transferase 1 (FDFT1), EF-hand calcium binding domain 4B (EFCAB4B), and glucokinase regulator (GCKR), are associated with NASH pathogenesis [23–25]. This evidence concerns the gene CRACR2A and metabolic dysfunction-associated steatotic liver disease.